Medically managed weight loss

GLP-1, or glucagon-like peptide-1, is a hormone naturally produced in the body that plays a crucial role in regulating appetite and calorie intake. Semaglutide is a synthetic drug that mimics the action of GLP-1. It is designed to enhance the body’s natural response to GLP-1, leading to reduced appetite and potentially significant weight loss. Semaglutide is used as an effective treatment in our weight management programs to help patients achieve their weight loss objectives.

The amount of weight loss achieved with Semaglutide can vary depending on several factors, including diet, lifestyle and adherence to the treatment plan. Clinical studies have shown that patients may lose on average 10-15% of their body weight. However, individual results can differ. During your consultation, we will discuss your specific goals and how Semaglutide can be integrated into your personalized weight management plan.

The timeline for seeing results from weight loss treatments like Semaglutide can vary by individual. Generally, patients may notice weight loss within the first few weeks of treatment. More significant results are often observed after continuing the treatment for several months. During your initial consultation, we will outline what you can expect and how to optimize your treatment plan for the best possible outcomes.

GLP-1 (glucagon-like peptide-1) is a hormone produced in the intestines that helps regulate blood sugar levels by stimulating insulin secretion, inhibiting glucagon secretion (which raises blood sugar), slowing gastric emptying, and promoting feelings of fullness.
GLP-1 agonists mimic the action of GLP-1 in the body by activating the same receptors. By doing so, they can help lower blood sugar levels, reduce appetite, and aid in weight loss. These medications are typically administered by injection, either subcutaneously or intravenously, and are often used in conjunction with other diabetes medications such as metformin. Some common examples of GLP-1 agonists include exenatide, liraglutide, dulaglutide, and semaglutide.

Medication shortages can occur due to various factors such as manufacturing issues, distribution challenges, or increased demand. Initially when there was an increase in demand for Ozempic as an off-label treatment for weight loss, there was a shortage specifically in the dispenser pens that are used for administering the medication. At this point in time the manufacturers have caught up with production and there is enough supply to meet demand.

The short answer is yes. GLP-1 agonists are primarily used for the treatment of type 2 diabetes mellitus. They work by mimicking the action of the hormone GLP-1, which helps regulate blood sugar levels. Research has shown their efficacy when used for weight loss and now this class of medications has been approved for treating both obesity and diabetes.

GLP-1 agonists, like any medication, can cause side effects in some people. Common side effects of GLP-1 agonists may include:


1. Nausea and vomiting: These are among the most common side effects, especially when starting treatment. They usually improve over time as your body adjusts to the medication.
2. Diarrhea or constipation: Changes in bowel habits can occur with GLP-1 agonists.
3. Decreased appetite: Some people may experience a reduced desire to eat, which can lead to weight loss. This is often considered a beneficial side effect, especially for individuals with obesity or overweight.
4. Hypoglycemia (low blood sugar): While GLP-1 agonists are not typically associated with hypoglycemia when used alone, they can increase the risk of low blood sugar when used in combination with other diabetes medications like insulin or sulfonylureas.
5. Injection site reactions: Redness, swelling, or itching at the injection site may occur.
6. Pancreatitis: In rare cases, GLP-1 agonists have been associated with pancreatitis, an inflammation of the pancreas.
7. Thyroid tumors: Some studies have suggested a potential risk of thyroid tumors with long-term use of GLP-1 agonists in rodents, but this risk has not been conclusively established in humans.

The use of GLP-1 agonists during pregnancy and breastfeeding is not well studied, and thus their safety in these situations is not fully established. Generally, GLP-1 agonists are not recommended for use during pregnancy due to potential risks to the developing fetus.

Here are some considerations regarding GLP-1 agonists and pregnancy/breastfeeding:

1. Pregnancy: There is limited data on the safety of GLP-1 agonists during pregnancy. Animal studies have shown adverse effects on pregnancy outcomes, including fetal harm, but these effects may not directly translate to humans. Due to the lack of sufficient data, GLP-1 agonists are usually not recommended for use during pregnancy unless the potential benefits outweigh the potential risks and alternative treatments are not suitable.
2. Breastfeeding: It is not known whether GLP-1 agonists pass into breast milk. Because of this uncertainty and the lack of data on the safety of these medications during breastfeeding, healthcare providers typically advise against their use while breastfeeding. If a woman needs to take a GLP-1 agonist while breastfeeding, close monitoring of the infant for any potential adverse effects may be warranted.

The length of time you will need to be taking this medication depends on various factors including how much weight you want to lose, your diet, exercise, sleep, hormones, medications you take and individual considerations concerning your health and mental health. Our team will work with you over time to design a program that is best suited to help you lose weight and get to a place of optimal health.

Keeping the weight off takes some work. However, if you commit to the lifestyle changes necessary to lose weight while on a GLP-1 agonist, then these should be part of your daily routine once you stop taking the medication. Continuing to life a healthy lifestyle including diet, exercise, sleep, stress management and hormone balance are key.

GLP-1 agonists are only covered on the provincial drug plans if you meet certain criteria including a diagnosis of diabetes and a trial of metformin. If you do not meet these criteria then you will need to pay the full price of the medication.

The cost depends on the amount of medication you take each month. Normally between $200-$300 CAD If you think about it, you can lose up to 5 pounds per week so it is like paying $10 per pound lost.

Sarcopenia is a medical term that refers to the age-related loss of muscle mass, strength, and function. It’s a natural part of the aging process, but it can have significant effects on a person’s quality of life, leading to decreased mobility, increased risk of falls and fractures, and reduced ability to perform activities of daily living. Sarcopenia can be influenced by factors such as hormonal changes, lack of physical activity, poor nutrition, and certain chronic illnesses. GLP-1 agonists can also cause sarcopenia. It is very important to address sarcopenia, especially while on a GLP-1 agonist through weight bearing exercise and proper nutrition. You must consume about 100g of protein a day and do resistance training for at least 30 minutes 3 times a week.